Physician profile
Renuka H Tank
NPI 1063430627
$1,419.80
in general payments reported to CMS, 2019-2025
16 companies · $751 in 2025
The $751 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.06 · 2021: $66.27 · 2022: $111 · 2023: $150 · 2024: $298 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.12 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $233.70 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $207.26 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $154.90 | 2023-2025 | Invega Sustenna, Spravato |
| Davol INC. | $150.00 | 2025 | Phasix Mesh |
| Teva Pharmaceuticals USA, INC. | $149.13 | 2022-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $127.05 | 2024-2025 | Cobenfy |
| Indivior INC. | $103.09 | 2021-2024 | Perseris, Sublocade |
| Otsuka America Pharmaceutical, INC. | $94.48 | 2021-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.43 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $34.40 | 2025 | Auvelity |
| Abbvie INC. | $21.67 | 2025 | |
| Lundbeck LLC | $18.13 | 2025 | Rexulti |
| Viiv Healthcare Company | $16.82 | 2024 | Cabenuva |
| Corium, LLC | $16.73 | 2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $15.22 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $14.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renuka Tank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.